Enlivex Therapeutics Ltd. Ordinary Shares - ENLV STOCK NEWS

Enlivex Therapeutics (Nasdaq: ENLV) announced a poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer from November 8-12, 2022, in Boston. The presentation titled “Synergistic anti-tumor effect of Allocetra–OTS, a cellular immune-therapy” is scheduled for November 10 and 11. Enlivex focuses on immunotherapy with its product Allocetra™, designed to reprogram macrophages to enhance immune response against cancer. For conference registration, visit the provided link.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its participation at the 4th Macrophage-directed Therapies Summit in Boston from October 4-6, 2022. The company's presentation is scheduled for October 6 at 2:30 PM ET, where management will discuss clinical programs targeting sepsis and solid cancers, along with supporting data. The summit will cover strategies to enhance macrophage therapies and facilitate discussions on clinical applications. Interested parties can register for the event here.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its participation in multiple investor conferences in September 2022. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 11:00 AM ET, and at Baird’s 2022 Global Healthcare Conference on September 14, 2022, at 3:10 PM ET. Additionally, Enlivex will engage in a panel discussion at the Cantor Cell and Genetic Medicines Conference on September 15, 2022, at 9:20 AM ET. Management will also be available for one-on-one meetings during these events.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced significant preclinical data at the ESMO Congress 2022, demonstrating that the combination of Allocetra™ with cisplatin resulted in a 55% survival rate in a murine mesothelioma model, compared to 0% in untreated and cisplatin monotherapy groups. These results support the ongoing Phase I/II trial of Allocetra™ combined with chemotherapy for patients with peritoneal metastases from solid tumors. Allocetra™ aims to reprogram macrophages to enhance anti-cancer responses.

Enlivex Therapeutics (Nasdaq: ENLV) announced on Sept. 6, 2022, that it received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application 15/551,284. This patent will enhance the company's intellectual property protection for Allocetra™, extending through at least 2036. Allocetra™ is aimed at inhibiting cytokine release syndrome in CAR T-cell therapy patients. The patent is expected to be granted by Q1 2023. CEO Oren Hershkovitz emphasized the significance of this patent in broadening Enlivex's valuable IP portfolio.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the issuance of a Notice of Allowance from the Japanese Patent Office for patent application number 2020-198242. This patent will grant intellectual property protection for the use of pooled donor cells in Allocetra™, extending protection until at least 2037. Enlivex aims to bolster its global IP strategy to enhance the commercial potential of Allocetra™, a reprogramming immunotherapy targeting diseases like sepsis and solid tumors. The patent is expected to be issued in Q2 2023, emphasizing Enlivex’s commitment to addressing unmet medical needs.

Enlivex Therapeutics has received regulatory clearance for amendments to its Phase II sepsis trial protocol in Israel, Spain, and Greece. The amendments introduce a frozen Allocetra™ formulation, improving shelf life and scalability, potentially lowering costs. The trial will now include patients with septic conditions beyond pneumonia, addressing a significant medical need, given that sepsis affects 1.7 million adults annually in the U.S. The company anticipates these changes may accelerate regulatory approval and commercialization timelines.

Enlivex Therapeutics announced significant advancements in its oncology and sepsis programs, highlighted by the dosing of the first patient in a Phase I/II trial assessing Allocetra™ with chemotherapy for patients with peritoneal metastases. The Israeli Ministry of Health approved a separate trial for Allocetra™ combined with a PD1 inhibitor. Preclinical studies indicate strong survival benefits in ovarian cancer and mesothelioma using Allocetra™. The company appointed Dr. Roger J. Pomerantz as Vice Chairman and maintains a solid financial position, with $62.5 million in cash as of June 30, 2022.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the Israeli Ministry of Health has approved a Phase I/II clinical trial for Allocetra™, aimed at patients with advanced solid tumors. This trial follows positive preclinical studies with Yale Cancer Center indicating significant survival benefits when Allocetra™ was combined with PD1 checkpoint inhibition. The trial will enroll up to 48 patients, evaluating safety, tolerability, and preliminary efficacy of Allocetra™ alone and combined with anti-PD1 therapy. The study addresses a significant unmet medical need in cancer treatment.